Innoviva, Inc. (INVA) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Innoviva’s revenue went from $134M in fiscal 2016 to $411M in fiscal 2025, growth of about 13.3% a year.
Net income in fiscal 2025 was $271M, a net margin of 65.9%; the best year in this period was 2018 with $395M.
Over the twelve months to September 30, 2026, revenue was $438M and net income $193M.
Free cash flow was $196M in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 31% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $438M | $411M | $359M | $310M | $331M | $392M | $337M | $261M | $261M | $217M | $134M |
| Gross profit | $326M | $308M | $296M | $246M | — | — | — | — | — | — | — |
| Operating income | $170M | $164M | $167M | $114M | $287M | $375M | $321M | $246M | $238M | $184M | $109M |
| Net income | $193M | $271M | $23M | $180M | $214M | $266M | $224M | $157M | $395M | $134M | $60M |
| EPS (diluted) | $2.35 | $3.30 | $0.36 | $2.20 | $2.37 | $2.87 | $2.02 | $1.43 | $3.53 | $1.17 | $0.53 |
| R&D | $20M | $31M | $14M | $34M | $41M | $576000 | $2M | $0 | $0 | $1M | $1M |
| Revenue growth | — | +14.7% | +15.5% | −6.3% | −15.4% | +16.4% | +29.0% | +0.0% | +20.2% | +62.6% | +147.6% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $183M | $197M | $189M | $141M | $202M | $364M | $313M | $257M | $224M | $142M | $61M |
| Capital spending | -$955000 | -$1M | -$270000 | -$411000 | -$67000 | $0 | -$13000 | -$12000 | $0 | $0 | -$278000 |
| Free cash flow | $183M | $196M | $188M | $141M | $202M | $364M | $313M | $257M | $224M | $142M | $61M |
| Dividends paid | — | — | — | — | — | $0 | $0 | $11000 | $80000 | $281000 | $960000 |
| Buybacks | $82M | $5M | $15M | $76M | $9M | $394M | $0 | $0 | $0 | $98M | $78M |
| Stock-based pay | $13M | $9M | $6M | $6M | $7M | $2M | $2M | $2M | $3M | $10M | $8M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $551M | $305M | $194M | $291M | $202M | $246M | $351M | $115M | $129M | $150M |
| Debt | — | $269M | $451M | $449M | $544M | $395M | $433M | $433M | $447M | $677M | $728M |
| Equity | — | $1.2B | $691M | $675M | $566M | $415M | $540M | $313M | $154M | -$243M | -$353M |
| Total assets | — | $1.6B | $1.3B | $1.2B | $1.2B | $926M | $1000M | $725M | $548M | $367M | $379M |
| Shares (diluted) | 72M | 85M | 74M | 87M | 95M | 94M | 114M | 113M | 113M | 120M | 123M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 74.5% | 74.8% | 82.6% | 79.2% | — | — | — | — | — | — | — |
| Operating margin | 38.8% | 39.8% | 46.5% | 36.7% | 86.6% | 95.7% | 95.3% | 94.4% | 91.3% | 84.5% | 81.6% |
| Net margin | 44.1% | 65.9% | 6.5% | 57.9% | 64.6% | 67.8% | 66.6% | 60.3% | 151.4% | 61.8% | 44.6% |
| FCF margin | 41.6% | 47.6% | 52.5% | 45.3% | 60.9% | 92.8% | 93.0% | 98.6% | 85.6% | 65.3% | 45.5% |
| ROIC | — | 9.4% | 9.1% | 9.4% | 19.9% | 38.4% | 27.4% | 27.1% | 31.3% | 42.3% | 29.0% |
| ROE | — | 23.1% | 3.4% | 26.6% | 37.8% | 64.1% | 41.6% | 50.2% | 257.2% | -55.2% | -16.9% |
Frequently asked questions
What is Innoviva’s annual revenue?
$411M in fiscal 2025 and $438M over the twelve months to September 30, 2026.
How much profit does Innoviva make?
Net income was $271M in fiscal 2025 (net margin 65.9%).
Is Innoviva’s revenue growing?
Yes: revenue rose 14.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.